Discover how we’re advancing biologics production to combat antimicrobial resistance (AMR). This presentation explores our comprehensive capabilities to support innovators, including support for monoclonal antibody, bacteriophage, recombinant protein, and microbiome production.
Learn about our end-to-end expertise in upstream development (scaling biologics expression), downstream development (purification processes), and analytical development and formulation, enabling seamless transition from discovery to commercialisation. Fill in the form to access the presentation.
To learn more, read about how innovation can stem the threat of antimicrobial resistance .



